You may also like
Hydroxyethyl Starch on Kidney and Haemostatic Function in Cardiac Surgical Patients: Is A Non-Inferiority Study Design Appropriate for This Setting?
In light of the existing concerns on HES use, this study leaves several unanswered questions: how should patients be informed when they are asked to participate in a clinical trial that may randomise them to receive HES? How can a prestigious research group consider it appropriate to adopt a ’non‐inferiority’ study design to evaluate the safety profile of a controversial drug such as HES, when any proven beneficial effects (if there are any) remain unanswered?
1 min read
The Pennsylvania Legislature Today Passed House Bills 500 and 501 Enacting Licensure of Perfusionists in Pennsylvania
The Pennsylvania Legislature today passed House Bills 500 and 501 enacting licensure of perfusionists in Pennsylvania.
1 min read
World Heart Gains FDA Approval for Novacor Changes
World Heart Corp. said on Wednesday it obtained pre-market approval from the U.S. Food and Drug Administration (FDA) for engineering changes to […]
1 min read